BioSpace News Archive

Under Argentina’s Presidency of the G20, leading economies in Latin America need to step up their contributions to fight against global AIDS and other related public-health threats

TRULANCE® second quarter net sales up over 40% versus prior quarter

Achieves program milestones as Orion clinical and R&D activities advance

Tandem Diabetes Care®, Inc. announced the closing of its previously announced underwritten public offering of 3,508,770 shares of common stock at a price to the public of $28.50 per share.

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial results for the second quarter ended June 30, 2018 and provided a corporate update.

Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule compound technologies, today announced that the Board of Directors has appointed Jim Scully as interim chief executive officer.

Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced that Dr. Dana Andersen has joined the company as Chief Technical and Manufacturing Officer.

Significant Increase in Operating Efficiency; Operating Expenses Decreased by 59%

Invacare Corporation reported results for the quarter ended June 30, 2018.

Rho, a full-service contract research organization (CRO), is offering a webinar highlighting tips on how to understand what is involved in a New Drug Application (NDA). The webinar will cover regulatory strategy, data integration and readiness, and electronic publishing, as well as tips that can help you avoid common pitfalls in the submissions process.